Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics

Inflamatix获得由D1 Capital Partners牵头的1.02亿美元D系列融资,用于将新型主机响应诊断技术商业化

2021-03-16 20:30:11 BioSpace

本文共1939个字,阅读需5分钟

BURLINGAME, Calif.---- Inflammatix, Inc., a pioneering molecular diagnostics company, announced today the closing of a $102 million Series D round of financing to support development and commercialization of its novel immune response diagnostics portfolio. D1 Capital Partners led the round, with participation from the company’s existing investors, including Northpond Ventures, Khosla Ventures, Think.Health, and OSF Healthcare Ventures. Sepsis caused more than five million deaths annually worldwide before the COVID-19 pandemic, and severe COVID-19 has been recognized as viral sepsis. In addition, antibiotic resistance is directly responsible for more than 700,000 deaths annually worldwide. Traditional methods for diagnosing acute infections are slow and are often inaccurate because they only look for pathogens in the bloodstream, despite the fact that most infections never enter the bloodstream. As a result, patients with suspected infection are often inappropriately treated with antibiotics, contributing to antibiotic resistance. Sepsis is often missed altogether. Inflammatix’s diagnostics rapidly read the patient’s immune response to infections across multiple mRNA biomarkers using machine learning algorithms. The company’s tests can identify the presence and type of infection (viral or bacterial), and the risk of severe disease, including severe COVID-19, to enable physicians to make more informed decisions. The tests are designed to be run on the company’s sample-to-answer, cartridge-based, point-of-care Myrna™ test system, which produces results in under 30 minutes. The funds will enable regulatory clearance and global commercialization of the Myrna system, and the InSep™ acute infection and sepsis test, which is designed to enable improved triage and decision-making in the emergency department and other acute care settings. Funds will also support continued development of the company’s pipeline of diagnostic tests, including the ViraBac EZ™ acute infection test. Virabac EZ is designed to be run from a simple fingerstick to identify whether a suspected infection is bacterial or viral, helping physicians in primary care, urgent care, and other outpatient clinical settings to determine when to prescribe antibiotics. “We are enthusiastic about the transformative potential of Inflammatix’s host response diagnostic approach to significantly improve two major issues in healthcare today: the inefficient, and often inaccurate, diagnosis of infection and sepsis, and the over-prescription of antibiotics,” said James Rogers, Analyst at D1 Capital Partners. “We are delighted to lead this round and look forward to the upcoming commercialization of the first of these novel tests, and to playing a role in the continued development of additional indications for this unique diagnostics approach.” “We are thrilled to welcome D1 Capital Partners to our strong investor syndicate, and look forward to bringing host response diagnostics to market,” said Inflammatix CEO and Co-Founder Tim Sweeney, M.D., Ph.D. “By quickly providing actionable information about disease, Inflammatix expects to equip physicians to make better clinical decisions that benefit both patients and healthcare systems.” About Inflammatix Inflammatix is a molecular diagnostics company that is reimagining diagnostics by reading the patient’s immune system to deliver rapid results that improve patient care and reduce major public health burdens. The company’s initial focus is on acute infections and sepsis, where its tests combine proprietary biomarkers and advanced machine learning to help physicians quickly get the right treatments to the right patients. Each test will be developed to run on the company’s sample-to-answer isothermal instrument platform, Myrna, in under 30 minutes, enabling the power of precision medicine at the point of care. The Burlingame, Calif.-based company is funded by Khosla Ventures, Northpond Ventures, D1 Capital Partners, Think.Health Ventures, the Stanford StartX Fund, and OSF Ventures. ViraBac EZ has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50119C00034. About D1 Capital Partners D1 Capital Partners is a global investment firm that operates across public and private markets. The firm combines the talent and operational excellence of a large, premier asset management firm with the flexible mandate and long-term time horizon of a family office. Founded in 2018 by Daniel Sundheim, D1 focuses on investing in the global internet, technology, telecom, media, consumer, healthcare, financial, industrial, and real estate sectors. View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005280/en/ Michelle McAdam, Chronic Communications, Inc. michelle@chronic-comm.com 310.902.1274 Mariesa Kemble kemblem@mac.com 608.850.4745 Source: Inflammatix View this news release online at: http://www.businesswire.com/news/home/20210316005280/en
Calif BURLINGAME----开创性的分子诊断公司Iflamatix,Inc.今天宣布结束1.02亿美元的D轮融资,以支持其新型免疫应答诊断产品组合的开发和商业化。D1 Capital Partners领导了这一轮投资,公司的现有投资者参与其中,包括Northpond Ventures、Khosla Ventures、Think.Health和OSF Healthcare Ventures。 在COVID-19大流行之前,脓毒症每年导致全球超过500万人死亡,重症COVID-19被认定为病毒性脓毒症。此外,抗生素耐药性直接导致全球每年70多万人死亡。诊断急性感染的传统方法速度慢且往往不准确,因为它们只在血流中寻找病原体,尽管事实上大多数感染从未进入血流。结果,疑似感染的患者往往不恰当地使用抗生素治疗,助长了抗生素耐药性。脓毒症常常被忽略。 Inflamatix的诊断学通过机器学习算法快速读取患者对多个mRNA生物标记物感染的免疫反应。该公司的检测可以识别感染(病毒或细菌)的存在和类型,以及包括严重COVID-19在内的严重疾病的风险,使医生能够做出更明智的决定。这些测试被设计在该公司的样本到答案、基于墨盒、护理点的Myrna™测试系统上运行,该系统在30分钟内产生结果。 这些资金将使Myrna系统和INSEP™急性感染和脓毒症试验得到监管许可和全球商业化,后者旨在改善急诊科和其他急性护理机构的分诊和决策。基金还将支持继续发展公司的诊断测试管道,包括ViraBac EZ™急性感染测试。Virabac EZ的设计是从一个简单的手指操作,以确定疑似感染是细菌感染还是病毒感染,帮助初级护理、紧急护理和其他门诊临床设置的医生确定何时开抗生素处方。 D1 Capital Partners公司的分析师詹姆斯·罗杰斯说:“我们对Inflamatix公司的宿主反应诊断方法的变革性潜力充满热情,它可以显著改善当今医疗保健领域的两个主要问题:感染和脓毒症的诊断效率低,而且往往不准确,以及抗生素处方过多。”“我们很高兴能领导这一轮测试,并期待着这些新测试中的第一项即将实现商业化,并在继续开发这种独特诊断方法的其他适应症方面发挥作用。” Inflamatix公司首席执行官兼联合创始人蒂姆·斯威尼博士说:“我们非常高兴地欢迎D1资本合作伙伴加入我们强大的投资者辛迪加,并期待着将主机响应诊断推向市场。“通过快速提供有关疾病的可操作信息,Inflamatix公司期望帮助医生做出更好的临床决策,使患者和医疗保健系统都受益。” 关于炎症 Inflamatix是一家分子诊断公司,通过读取患者的免疫系统来重新想象诊断方法,以提供快速的结果,改善患者的护理并减轻主要的公共卫生负担。该公司最初的重点是急性感染和败血症,其测试结合了专有的生物标志物和先进的机器学习,帮助医生迅速为正确的患者提供正确的治疗。每项测试将在30分钟内在公司的样本-答案等温仪器平台Myrna上运行,从而在护理点上实现精准医学的功能。这家总部位于加州伯林盖姆的公司由Khosla Ventures,Northpond Ventures,D1 Capital Partners,Think.Health Ventures,Stanford StartX Fund和OSF Ventures提供资金。 ViraBac EZ的全部或部分资金来自卫生和公众服务部的联邦资金;负责备灾和反应的助理秘书办公室;生物医学高级研究和发展管理局,合同号75A50119C00034。 关于D1 Capital Partners D1 Capital Partners是一家全球性投资公司,在公共和私人市场开展业务。该公司结合了大型卓越资产管理公司的人才和卓越运营能力,以及家族办公室的灵活授权和长期业务。D1由Daniel Sundheim于2018年创立,专注于投资全球互联网、科技、电信、媒体、消费、医疗保健、金融、工业和房地产领域。 在businesswire.com上查看源版本:https://www.businesswire.com/news/home/20210316005280/en/ Michelle McAdam,慢性通信公司。 电子邮件:michelle@chronic-comm.com 310.902.1274 玛丽莎·肯布尔 电子邮件:kemblem@mac.com 608.850.4745 来源:inflamatix 请在以下网址联机查看此新闻稿: http://www.businesswire.com/news/home/20210316005280/en

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文